Vivasure Medical, a Galway, Eire-based firm targeted on absorbable expertise for percutaneous vessel closure, acquired a €30m strategic funding from Haemonetics Company (NYSE: HAE) as a part of its beforehand disclosed Sequence D financing.
Haemonetics joined Fountain Healthcare Companions, Orchestra BioMed Holdings, LSP Well being Economics Fund, Panakès Companions, Evonik Enterprise Capital, Enterprise Eire, and European Funding Financial institution.
The corporate intends to make use of the scientific research outcomes to help an FDA pre-market approval submission in addition to multinational industrial launch of the PerQseal system for big gap vessel closure.
Led by CEO Andrew Glass, Vivasure is targeted on the event of superior polymer implants and supply techniques, primarily targeted on minimally invasive vessel closure in cardiology, interventional radiology and vascular surgical procedure. PerQseal is designed to be the primary sutureless, absolutely absorbable artificial implant for large-bore vessel punctures. Its low profile patch might be positioned from contained in the vessel and is meant to make deployment less complicated and extra managed than typical closure strategies. Medical research up to now have proven a low complication charge and excessive technical success.
The corporate operates a totally built-in R&D and ISO 13485 licensed manufacturing facility and is backed by main worldwide medtech traders.
Vivasure Medical has additionally acquired help from Enterprise Eire and the European Funding Financial institution.
FinSMEs
13/03/2023
